Table 1 PICOS Criteria for Study Selection

Population

Patients with LABC or MBC who had received at least one prior therapy

•. LABC or MBC defined as stage IV, any T, and N, M1^a

•. Target populations were HER2-negative or TNBC, but HER2-positive populations were also included

•. Early disease (stage I–III)

•. First-line treatment

Interventions

•. Eribulin mesylate (Halaven®)

•. Carboplatin (Paraplatin®)

•. Cisplatin (Platinol®; Platinol®-AQ)

•. Cyclophosphamide (Cytoxan®; Neosar®)

•. Doxorubicin (Adriamycin®; Rubex®)

•. Doxorubicin liposomal (Doxil®)

•. Epirubicin (Ellence®)

•. Capecitabine (Xeloda®)

•. Fluorouracil (Adrucil®)

•. Gemcitabine (Gemzar®)

•. Methotrexate (amethopterin)

•. Docetaxel (Taxotere®)

•. Ixabepilone (Ixempra®)

•. Paclitaxel (Taxol®; Onxal™)

•. Protein-bound paclitaxel (Abraxane®)

•. Vinorelbine (Navelbine®)

Interventions not of interest or administered in combination with interventions of interest

Comparators

BSC, placebo, or all therapies listed above as monotherapy or in combination with other treatments for LABC/MBC

Outcomes

•. Efficacy: OS, PFS, response (including ORR, CR, PR, SD, PD)

•. Safety: AEs, SAEs, discontinuation, and death

Studies not reporting any outcomes of interest

Study Design

RCTs

Observational studies (including but not limited to case controls, prospective and retrospective cohorts, cross-sectional studies, single-arm trials, SLRs, NMAs, dose-escalation studies)

Countries

Any

NA